Company Profile
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Latest News
3Shape's TRIOS MOVE Pro Scanner Cart Wins Red Dot 2026 Design Award
AI Usage Among 7th Gen Galaxy Foldables Users Grows in Southeast Asia and Oceania as Mobile Continues to be the Primary Gateway to AI
Take Five: A crude summer
Bank of England to keep rate steady despite oil and gas price rebound
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.torrentpharma.com |
| Audit Risk | 2 |
| Board Risk | 3 |
| Overall Risk | 3 |
| Market Cap | 1.91T |
| Trailing P/E | 78.34 |
| Forward P/E | 53.35 |
| Dividend Rate | 38 |
| Dividend Yield | 0.77% |
| Trailing Annual Div. Rate | 38 |
| Trailing Annual Div. Yield | 0.77% |
| Trailing EPS | 64 |
| Forward EPS | 93.97 |
| Book Value | 247.85 |
| Price-to-Book | 20.23 |
| Enterprise-to-Revenue | 13.58 |
| Enterprise-to-EBITDA | 42.21 |
| Ex-Dividend Date | 05/29/2026 |
| Earnings Date | 07/30/2026 |
| Earnings Call Date | 07/30/2026 |
| Earnings Average | 14.93 |
| Earnings Low | 11.7 |
| Earnings High | 17.1 |
| Revenue Average | 47.17B |
| Revenue Low | 43.55B |
| Revenue High | 48.32B |